Jason Karlawish

speaker

1,378 appearances 5 recordings 1 series first heard Feb 2021 last heard Dec 2023

Jason Karlawish’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

No recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.

newest first · ▶ plays the moment

Janet Woodcock, the acting commissioner.

Essentially as I best as I can tell, says I was not really following this.

I was busy with Operation Warp Speed and other things.

And my response to that, if I was in the Senate or the House, would be Alzheimer's is one of the top killers.

Prevalent disease costly.

Arguably sort of the the covet of long term care.

And you were not at all apprised of this decision that knew that would be earth shattering?

I I you know, I I have to say at least she at least dropped the ball on this one.

But anyway, I don't want to make it about Janet Woodcock.

The process that has unfolded at FDA has multiple moments where it just raises real questions of the question, what's going on at FDA?

Because

The data that describe

uh the reduction of amyloid

Ніц relationship to clinical uh uh course.

Are still a work in progress, both when done in experiments like Adahelm and other drugs.

Uh uh number one and number two.

Amyloid accumulation occurs up to ten years prior to symptomatic onset.

By the time symptoms are occurring, amyloid accumulation essentially has peaked out.

And so the idea that reduction of an alteration in amyloid is like the C D four count, if you will, of HIV.

Reduce it, the patient does better, or LDL, pick your it you start to sort of leap across metaphors or stories that just don't hold up anymore.

Showing 861–880 of 1,378 · page 44 of 69